Orexigen Therapeutics - Investment summary: LIGHT ahead

Friday, Dec 21 2012 by

Dec 21st 2012 - Edison Investment Research today published a report on Orexigen Therapeutics entitled "Investment Summary: LIGHT Ahead". In summary, the report says:

With the screening completed of 13,192 patients for the cardiovascular outcome trial (CVOT), LIGHT, Orexigen is on track to enrol c 10,400 and randomise c 9,000 patients by 1 January and 15 January 2013 respectively. An interim analysis of the trial could occur in between Q2-Q413, making the data available for FDA two to three months thereafter. We believe the LIGHT study has a high probability of generating positive outcome and ultimately leading to an approval in the US.

About Edison Investment Research

Edison Investment Research


Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »